Kidney Transplant Endpoints Strive For Acceptance At FDA Workshop
Traditional endpoints are becoming increasingly difficult to use successfully in clinical trials because the standard of care has become highly effective.
You may also be interested in...
FDA is considering the use of 30% and 40% reductions in glomerular filtration rate as surrogate endpoints for the development of kidney failure in clinical trials; the current standard is 50%.
Sponsors cannot cut corners in developing clinical data to support a revised dosing scheme, even when a drug’s efficacy has already been shown, Novartis learned while shepherding its kidney transplant agent Zortress (everolimus) through the FDA approval process.
Less than a year after signing a consent decree to resolve compliance problems, the company is forced to stop manufacturing its generic version of the best-selling cholesterol drug. For FDA, the issue poses a public relations challenge since it touches on several areas where the agency has recently been criticized – generic drug quality, manufacturing oversight and drug shortages.